Choices and clinical trials in early kidney cancer therapy
Download
1 / 6

Choices and clinical trials in early kidney cancer therapy - PowerPoint PPT Presentation


  • 140 Views
  • Uploaded on

Choices and clinical trials in early kidney cancer therapy. E2805 adjuvant sorafenib of sunitinib or placebo post surgery open at CPMC ARISER - Adjuvant Rencarex (WX-G250) intravenous monoclonal antibody available at UCSF .

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Choices and clinical trials in early kidney cancer therapy' - karena


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Choices and clinical trials in early kidney cancer therapy

Choices and clinical trials in early kidney cancer therapy

E2805 adjuvant sorafenib of sunitinib or placebo post surgery open at CPMC

ARISER - Adjuvant Rencarex (WX-G250) intravenous monoclonal antibody available at UCSF


Choices first line therapy for stage iv kidney cancer
Choices First-line Therapy for Stage IV kidney cancer

  • High-dose Interleukin-2-most toxic

  • Sunitinib (Sutent) oral, moderate side effects

  • Sorabenib (Nexavar) oral, fewer side effects

  • Bevacizumab with interferon-final data available this summer

  • Interferon alone- inferior

  • Temsirolimus (Torisel) probably available this spring

  • Clinical Trial


Clinical trials what and why
Clinical Trials: What and Why

  • Phase I, Phase II, Phase III-decreasing risk

  • A biologic experiment with humans

  • Access to a new therapy that may be better

  • Access to expertise not available next door

  • Closer monitoring of your cancer and of treatment side effects

  • Choose a trial specifically for kidney cancer


Trials at california kidney cancer center 2007
Trials at California Kidney Cancer Center 2007

  • Renal EFFECT trial--first line stage 4 2 different doses of sunitinib 50mg/day 4weeks on, 2 off 37.5 mg/day, every day

  • TRIST trial Trovax vaccine with sunitinib

  • RAD001 trial mTOR inhibitor 2nd, 3rd line versus placebo

  • E2805 adjuvant study stage 2 or 3 post-op


Choices for second line therapy

Choices for second-line therapy

Clinical Trial

Temsirolimus vs. sorafenib after sunitinib- trial planned

Immunotherapy with high-dose IL-2

Change from sorafenib/sunitinib to bevacizumab

Change from bevacizumab to sorafenib or sunitinib

Change from immunotherapy to targeted therapy

Temsirolimus (Torisel)


Combinations of targeted therapies
Combinations of Targeted Therapies

  • Sorafenib with bevacizumab phase 1 toxicities required dose reductions 42% response rate

  • Sunitinib with bevacizumab trial in progress

  • Temsirolimus with bevacizumab

    trial planned

  • Temsirolimus with sorafenib in progress

    Phase III trial planned

  • Many other combinations possible